Rebion is a groundbreaking brand that offers a Window to the Brain, providing a crucial tool for identifying and managing life-altering diseases related to brain impairment or damage. Backed by extensive research and trials at top medical institutions, Rebion introduces the Neural Performance Scanning (NPS) technology, which revolutionizes disease detection and management. NPS uses retinal scanning to measure bilateral fixation and saccadic movement, allowing for instant identification of brain malfunction.

Rebion's first commercial product is the blinq. ® vision scanner, the only device cleared by the FDA to detect amblyopia and strabismus (lazy eye). In just seconds, this transformative device measures eye fixation, making it a crucial tool for early detection of pediatric vision loss and monocular vision loss in adults.

Additionally, Rebion is currently in pivotal clinical trials for their Traq. ™ device, which focuses on identifying physical and structural disruptions in the brain-eye pathway caused by traumatic brain injury (TBI), including concussion. This measurement provides an objective assessment of the neurophysiological mechanisms tied to the detection, characterization, and longitudinal monitoring of TBI.

Rebion's portable, point-of-care devices offer previously unavailable information, enabling fast and impactful triage, early disease detection, intervention, and tailored treatments. By making these advancements more accessible, Rebion is at the forefront of improving the lives of individuals with brain-related conditions